Your browser doesn't support javascript.
loading
Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis.
Hong, Namki; Kim, Jo Eun; Lee, Su Jin; Kim, Se Hwa; Rhee, Yumie.
Afiliação
  • Hong N; Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Korea.
  • Kim JE; Graduate School, Yonsei University College of Medicine, Seoul, Korea.
  • Lee SJ; Department of Internal Medicine, Gimpo Woori Hospital, Gimpo, Gyeonggi-do, Korea.
  • Kim SH; Department of Internal Medicine, Ilsan Hospital, Koyang, Korea.
  • Rhee Y; Department of Internal Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Korea.
Clin Endocrinol (Oxf) ; 88(5): 652-658, 2018 05.
Article em En | MEDLINE | ID: mdl-29389010
CONTEXT: Teriparatide (TPTD) therapy has been proposed as a potential treatment strategy in severe cases of pregnancy- and lactation-associated osteoporosis (PLO) characterized by the occurrence of fragility fractures in the third trimester or early postpartum. OBJECTIVE: To investigate the changes in bone mineral density (BMD) and bone turnover markers in patients with PLO with and without TPTD treatment. DESIGN: Retrospective cohort study. PATIENTS: Thirty-two patients with PLO who presented with multiple vertebral fractures to a tertiary institution between 2007 and 2015 were included. MEASUREMENTS: Changes in BMD at the lumbar spine (LSBMD) and proximal femur after 12 months of daily subcutaneous injections of 20 µg TPTD (n = 27) were assessed. Subjects who rejected the TPTD treatment were used as controls (n = 5). RESULTS: LSBMD increased in both subjects treated with TPTD and controls, with greater increases in the TPTD group (15.5 ± 6.6% vs 7.5 ± 7.1%, P = .020) after adjustment for age and baseline LSBMD. During follow-up, serum levels of osteocalcin (OCN) and C-telopeptide of type I collagen (CTX) increased significantly in the TPTD group. In multivariate linear regression models, TPTD treatment (adjusted ß = 7.92, P = .032) and younger age (adjusted ß = 1.06, P = .046), but not baseline LSBMD, body mass index, serum OCN level and CTX level, were independently associated with greater increases in LSBMD. CONCLUSIONS: In patients with PLO, LSBMD at 12 months increased in both the TPTD-treated and control groups. TPTD treatment and younger age were associated with greater increases in LSMBD irrespective of baseline LSBMD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose / Biomarcadores / Densidade Óssea / Teriparatida Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose / Biomarcadores / Densidade Óssea / Teriparatida Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Pregnancy Idioma: En Ano de publicação: 2018 Tipo de documento: Article